BACKGROUND: The applicability of clinical trial findings (efficacy) to the routine care setting (effectiveness) may be limited because of study eligibility criteria and volunteer bias. Although well-chronicled in many conditions, the efficacy versus effectiveness of antiretroviral therapy (ART) remains understudied. METHODS: A retrospective study of the University of Alabama at Birmingham 1917 Clinic Cohort evaluated ART-naive patients who started ART from 1 January 2000 through 31 December 2006. Patients received ART through clinical trials or routine care. Multivariable logistic and linear regression models were fit to evaluate factors associated with virological failure (virological failure was defined as a viral load >50 copies/mL) and change from baseline CD4+ cell count 6 and 12 months after ART initiation. Sensitivity analyses evaluated the impact of missing data on outcomes. RESULTS: Among 570 patients starting ART during the study period, 121 (21%) enrolled in clinical trials, and 449 (79%) received ART via routine care. ART receipt through routine care was not associated with viral failure at either 6 months (odds ratio [OR], 1.00; 95% confidence interval [CI], 0.54-1.86) or 12 months (OR, 1.56; 95% CI, 0.80-3.05) in primary analyses. No statistically significant differences in CD4+ cell count responses at 6 and 12 months were observed. CONCLUSIONS: Although marked differences in efficacy versus effectiveness have been observed in the therapeutic outcomes of other conditions, our analyses found no evidence of such divergence among our patients who initiated antiretroviral therapy for human immunodeficiency virus infection.
BACKGROUND: The applicability of clinical trial findings (efficacy) to the routine care setting (effectiveness) may be limited because of study eligibility criteria and volunteer bias. Although well-chronicled in many conditions, the efficacy versus effectiveness of antiretroviral therapy (ART) remains understudied. METHODS: A retrospective study of the University of Alabama at Birmingham 1917 Clinic Cohort evaluated ART-naive patients who started ART from 1 January 2000 through 31 December 2006. Patients received ART through clinical trials or routine care. Multivariable logistic and linear regression models were fit to evaluate factors associated with virological failure (virological failure was defined as a viral load >50 copies/mL) and change from baseline CD4+ cell count 6 and 12 months after ART initiation. Sensitivity analyses evaluated the impact of missing data on outcomes. RESULTS: Among 570 patients starting ART during the study period, 121 (21%) enrolled in clinical trials, and 449 (79%) received ART via routine care. ART receipt through routine care was not associated with viral failure at either 6 months (odds ratio [OR], 1.00; 95% confidence interval [CI], 0.54-1.86) or 12 months (OR, 1.56; 95% CI, 0.80-3.05) in primary analyses. No statistically significant differences in CD4+ cell count responses at 6 and 12 months were observed. CONCLUSIONS: Although marked differences in efficacy versus effectiveness have been observed in the therapeutic outcomes of other conditions, our analyses found no evidence of such divergence among our patients who initiated antiretroviral therapy for human immunodeficiency virus infection.
Authors: M Lichterfeld; A Wöhrmann; N Schmeisser; G Fätkenheuer; B Salzberger; C Wyen; K Schmitz; T Sauerbruch; J K Rockstroh Journal: Eur J Med Res Date: 2003-02-21 Impact factor: 2.175
Authors: Marjo Hordijk-Trion; Mattie Lenzen; William Wijns; Peter de Jaegere; Maarten L Simoons; Wilma J M Scholte op Reimer; Michel E Bertrand; Nestor Mercado; Eric Boersma Journal: Eur Heart J Date: 2006-01-19 Impact factor: 29.983
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Jorge Luis Salinas; Herman Vildozola Gonzales; Juan Astuvilca; Yanet Arce-Villavicencio; Danny Carbajal-Gonzalez; Lety Talledo; James H Willig Journal: Am J Trop Med Hyg Date: 2011-12 Impact factor: 2.345
Authors: Michael J Mugavero; Margaret May; Heather J Ribaudo; Roy M Gulick; Sharon A Riddler; Richard Haubrich; Sonia Napravnik; Sophie Abgrall; Andrew Phillips; Ross Harris; M John Gill; Frank de Wolf; Robert Hogg; Huldrych F Günthard; Geneviève Chêne; Antonella D'Arminio Monforte; Jodie L Guest; Colette Smith; Javier Murillas; Juan Berenguer; Christoph Wyen; Pere Domingo; Mari M Kitahata; Jonathan A C Sterne; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2011-11-01 Impact factor: 3.731
Authors: Klaus Jansen; Anders Sönnerborg; Norbert Brockmeyer; Anders Thalme; Veronica Svedhem; Stephan Dupke; Jean-Luc Eychenne; Tina Nakonz; Maria Jesus Jimenez-Exposito; Pascal Pugliese Journal: AIDS Res Hum Retroviruses Date: 2012-11-27 Impact factor: 2.205
Authors: James H Willig; Inmaculada Aban; Christa R Nevin; Jiatao Ye; James L Raper; James A McKinnel; Lori L Delaitsch; Joseph M Mrus; Guy R De La Rosa; Michael J Mugavero; Michael S Saag Journal: AIDS Res Hum Retroviruses Date: 2010-10-21 Impact factor: 2.205
Authors: Lindsay J L Forbes; Alice S Forster; Rachael H Dodd; Lorraine Tucker; Rachel Laming; Sarah Sellars; Julietta Patnick; Amanda J Ramirez Journal: J Cancer Epidemiol Date: 2012-11-07